Testing BMX-001 for Head and Neck Cancer Chemoradiation Side Effects
This study is testing if adding the drug BMX-001, or a placebo (an inactive substance), to your usual chemoradiation therapy can help reduce severe oral mucositis (mouth sores and inflammation) in patients with head and neck cancer. Oral mucositis is a common and painful side effect of treatment. BMX-001 works by neutralizing harmful substances in the body that can damage healthy tissues. We are looking for about 98 participants with certain types of head and neck cancer, including HPV-mediated oropharyngeal carcinoma. The main goal is to see if BMX-001 can lower the number of people who get severe mouth sores during and after treatment. The current status of this study is unclear.
- Study design
- This interventional study plans to enroll 98 participants. It compares BMX-001 to a placebo alongside standard chemoradiation.
- What's involved
- You would receive usual symptom management, undergo blood, serum, and/or plasma sample collection, CT scans, and image-guided radiation therapy. You would also receive cisplatin.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint measures severe oral mucositis from the start of radiation through 4 weeks after treatment, with additional assessments at 6, 8, and 12 weeks after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT06532279
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Recruiting
PHASE2Ages 18+InterventionalSupportive careNRG OncologyInvestigator-initiated
~98 participants
Updated 2026-08-17 on ClinicalTrials.gov
What's tested:Best PracticeBiospecimen CollectionCisplatinComputed TomographyImage Guided Radiation TherapyIntensity-Modulated Radiation Therapy
At a glance
Recruiting sites
146 of 153 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of severe oral mucositis (SOM)
Measured over From start of radiation through 4 weeks after completion of study treatment
Conditions
Where it's being run
153 sites across 30 statesIllinois24
Pennsylvania19
Wisconsin14
North Carolina12
Florida11
Iowa11
Michigan11
California7
Study leadership
- David M Brizel · PRINCIPAL_INVESTIGATOR · NRG Oncology
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Patients must be planned to receive radiation and concurrent cisplatin chemotherapy as definitive therapy. Patients planned to receive concurrent cisplatin and radiation therapy in the adjuvant setting are not eligible.
At least two subsites (buccal mucosa, lips, retromolar trigone, floor of mouth, oral tongue, tonsil, soft palate, or hard palate) must have at least 1cc or 1% of the subsite volume receiving \>= 50 Gy. In cases of uncertainty, the enrolling clinician can ensure coverage by inspecting the 50 Gy isodose line and using the table describing the anatomic boundaries of the individual subsites contained within the extended cavity contour. The two or more subsites receiving \>= 50 Gy must be documented by the enrolling physician.
Pathologically confirmed (histologically or cytologically) squamous cell carcinoma of the oropharynx, larynx, hypopharynx, nasopharynx, or oral cavity.
P16 and/or human papillomavirus (HPV) status (via polymerase chain reaction \[PCR\] or in situ hybridization \[ISH\]) must be documented for patients with oropharynx cancer.
No patients with T0/Tx/unknown primary disease.
No definitive clinical or radiologic evidence of metastatic (M1) disease related to current diagnosis.
Able to receive intensity-modulated radiation therapy (IMRT) delivered as daily fractions of 2.0 Gy once per weekday with a cumulative radiation dose of 70 Gy.
Age \>= 18.
Zubrod performance status of 0-2.
Potassium ≥ institutional lower limit of normal (LLN) and magnesium ≥ institutional LLN. Oral or intravenous (IV) replacement therapy of potassium or magnesium is permitted if parameters can be met after repletion.
Absolute neutrophil count (ANC) \>= 1,500 cells/mm\^3.
Platelets \>= 100,000 cells/mm\^3.
Hemoglobin \>= 9.0 g/dl (Note: The use of transfusion or other intervention to achieve hemoglobin \[Hgb\] \>= 10.0 g/dl is acceptable).
Adequate renal function defined as creatinine clearance (CrCL) \> 50 mL/min by the Cockcroft-Gault formula.
Total bilirubin =\< 2 x institutional upper limit of normal (ULN) (not applicable to patients with known Gilbert's syndrome).
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 3 x institutional ULN.
No prior radiotherapy that would result in overlap of radiation treatment fields with planned treatment for study cancer, e.g., breast cancer with irradiation of the supraclavicular fossa/level 4 neck.
No concurrent treatment with nitrates or other drugs that may, in the judgment of the treating investigator, create a risk for a precipitous decrease in blood pressure.
No prior history of gross total excision of both primary and nodal disease; this includes tonsillectomy, local excision of primary site, and nodal excision that removes all clinically and radiographically evident disease. In other words, to participate in this protocol, the patient must have clinically or radiographically evident gross disease for which disease response can be assessed.
No current treatment of adjuvant post-operative (op) chemoradiation.
No systemic treatment with inducers or strong inhibitors of cytochrome P450 =\< 4 days before registration. Note: Patients undergoing steroid treatment as a component of the anti-emetic regimen for cisplatin are eligible for the study. Treatment with the antifungal medications, nystatin, fluconazole , miconazole and clotrimazole are allowed.
No prior induction chemotherapy treatment.
No prior unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ, basal cell skin carcinoma, resected T1-2N0M0 differentiated thyroid cancers, Ta bladder cancers, or low risk prostate cancer.
No clinically significant hearing impairment that precludes cisplatin, as per physician assessment.
No serious cardiovascular disease or cerebrovascular disease in the last 6 months prior to study enrollment; defined as a cerebrovascular accident, myocardial infarction, unstable angina, serious cardiac arrhythmia uncontrolled by medication or with the potential to interfere with protocol treatment, or current New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF), or admission within last 6 months for CHF exacerbation; (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification).
No valvular heart disease.
No significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to enrollment.
No history or evidence upon physical/neurological examination of central nervous system disease (e.g., seizures) unrelated to cancer unless adequately controlled by medication.
No acute bacterial, viral, or fungal infection requiring intravenous antimicrobials within 7 days of enrollment.
No history of chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of registration.
No known personal or family history of long QT Syndrome; no marked baseline prolongation of QT/corrected QT (QTc) interval (i.e., ≥ 2 electrocardiograms \[EKGs\] in prior 3 months of a QTc interval \> 450 milliseconds (ms) for males and \> 470 ms for females using the specific/usual choice by clinical center for correction factor.
Persistent grade 3-4 (CTCAE version 5.0) electrolyte abnormalities must be reversible to ≤ grade 1 with supplementation.
No poorly controlled hypertension (systolic blood pressure \[SBP\] \> 160 and/or diastolic blood pressure \[DBP\] \> 95) over 2 repeated measures within 30 days prior to registration.
No grade \>= 2 oral mucositis per CTCAE version 5.0.
No grade \>= 2 hypotension per CTCAE v. 5.0.
No medical necessity for anti-arrhythmics with significant risk of QTc prolongation such as class I and class III anti-arrhythmics. These include but are not limited to amiodarone, quinidine, dofetilide, sotalol, flecainide, and lidocaine.
No medical necessity for medications listed as prohibited.
For standard management of oral mucositis, clinicians may consult the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy. The only intervention against mucositis that is supported by level I evidence is low-level laser therapy (LLLT). Honey is rated at level II and benzydamine, which isn't available in the United States (US), is rated at level III. There are no other positively rated interventions.
LLLT is prohibited in this study as its availability remains limited, it is not Food and Drug Administration (FDA) approved in the US, and it is considered investigational in many circumstances requiring enrollment in a dedicated protocol who requirements could conflict with this one. Therefore, institutions that use LLLT should only enroll patients who would not be eligible for (or do not want) that intervention. Honey is not on the list of prohibited medications for this study. Given the MASCC recommendation, benzydamine is allowed, although there is lack of availability in the United States of America (USA). The other listed prohibited medications are not recommended by MASCC and some are potentially harmful, such as glutamine, which is associated with mortality in patients receiving stem cell transplant.
No history of allergic reaction to the study agent(s), compounds of similar chemical or biologic composition to the study agent (s) (or any of its excipients).
Childbearing potential is defined as any person who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal.
What this trial measures
- Incidence of severe oral mucositis (SOM)From start of radiation through 4 weeks after completion of study treatment
Proportion of patients with reported SOM \>= grade 3 per World Health Organization criteria.